A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents

• Farah C.S.
• Balasubramaniam R.
• McCullough M.J.

Contemporary Oral Medicine: A Comprehensive Approach to Clinical Practice.

Springer International Publishing,
2019

• Georgakopoulou E.
• Scully C.

Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.

Br Dent J. 2015; 218: 671-677

• Mays J.W.
• Carey B.P.
• Posey R.
• et al.

World Workshop of Oral Medicine VII: a systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus.

Oral Dis. 2019; 25: 111-121

• Gueiros L.A.
• France K.
• Posey R.
• et al.

World Workshop on Oral Medicine VII: immunobiologics for salivary gland disease in Sjögren’s syndrome—a systematic review.

Oral Dis. 2019; 25: 102-110

• Singh J.A.
• Wells G.A.
• Christensen R.
• et al.

Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Cochrane Database Syst Rev. 2011; 2: CD008794

• Findeisen K.E.
• Sewell J.
• Ostor A.J.K.

Biological therapies for rheumatoid arthritis: an overview for the clinician.

Biologics. 2021; 15: 343-352

• Chebli J.M.
• Gaburri P.D.
• Chebli L.A.
• et al.

A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.

Med Sci Monit. 2014; 20: 487-498

• Kane S.V.

Preparing for biologic or immunosuppressant therapy.

Gastroenterol Hepatol (N Y). 2011; 7: 544-546

• Ahmed Ali U.
• Martin S.T.
• Rao A.D.
• Kiran R.P.

Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn’s disease.

Dis Colon Rectum. 2014; 57: 663-674

• Yung D.E.
• Horesh N.
• Lightner A.L.
• et al.

Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease.

Inflamm Bowel Dis. 2018; 24: 2327-2338

• Law C.C.Y.
• Narula A.
• Lightner A.L.
• McKenna N.P.
• Colombel J.F.
• Narula N.

Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease.

J Crohns Colitis. 2018; 12: 538-545

• Kotze P.G.
• Ma C.
• Mckenna N.
• et al.

Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis.

Therap Adv Gastroenterol. 2018; 111756284818783614

• Lightner A.L.
• McKenna N.P.
• Alsughayer A.
• et al.

Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn’s patients.

J Pediatr Surg. 2019; 54: 2162-2165

• Lightner A.L.
• McKenna N.P.
• Alsughayer A.
• et al.

Biologics and 30-day postoperative complications after abdominal operations for Crohn’s disease: are there differences in the safety profiles?.

Dis Colon Rectum. 2019; 62: 1352-1362

• Shah R.S.
• Bachour S.
• Jia X.
• et al.

Hypoalbuminaemia, not biologic exposure, is associated with postoperative complications in Crohn’s disease patients undergoing ileocolic resection.

J Crohns Colitis. 2021; 15: 1142-1151

• Yang Z.
• Wu Q.
• Wu K.
• Fan D.

Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.

Aliment Pharmacol Ther. 2010; 31: 486-492

• Yang Z.
• Wu Q.
• Wang F.
• Wu K.
• Fan D.

Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery.

Aliment Pharmacol Ther. 2012; 36: 922-928

• Zaghiyan K.
• McGovern D.
• Fleshner P.

Should biologic agents be stopped before surgery for inflammatory bowel disease?.

Expert Rev Gastroenterol Hepatol. 2015; 9: 269-272

• George M.D.
• Baker J.F.
• Winthrop K.
• et al.

Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty: a cohort study.

Ann Intern Med. 2019; 170: 825-836

• Diaper R.
• Wong E.
• Metcalfe S.A.

The implications of biologic therapy for elective foot and ankle surgery in patients with rheumatoid arthritis.

Foot (Edinb). 2017; 30: 53-58

• Menter A.
• Strober B.E.
• Kaplan D.H.
• et al.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

J Am Acad Dermatol. 2019; 80: 1029-1072

CDT. Code on Nomenclature (CDT) Code. American Dental Association. Accessed August 30, 2022. https://www.ada.org/publications/cdt

• Georgakopoulou E.A.
• Scully C.

Orofacial adverse effects of biological agents.

J Investig Clin Dent. 2015; 6: 252-260

• Apte R.S.
• Chen D.S.
• Ferrara N.

VEGF in signaling and disease: beyond discovery and development.

Cell. 2019; 176: 1248-1264

• Stanca Melincovici C.
• Boşca A.B.
• Şuşman S.
• et al.

Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis.

Rom J Morphol Embryol. 2018; 59: 455-467

• Jain R.K.

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Science. 2005; 307: 58-62

• Jain R.K.

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

Cancer Cell. 2014; 26: 605-622

• Falavarjani K.G.
• Nguyen Q.D.

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Eye (Lond). 2013; 27: 787-794

• Eguia A.
• Bagán-Debón L.
• Cardona F.

Review and update on drugs related to the development of osteonecrosis of the jaw.

Med Oral Patol Oral Cir Bucal. 2020; 25: e71-e83

• Zarringhalam P.
• Brizman E.
• Shakib K.

Medication-related osteonecrosis of the jaw associated with aflibercept.

Br J Oral Maxillofac Surg. 2017; 55: 314-315

• Takano S.
• Uchida K.
• Inoue G.
• et al.

Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis.

BMC Musculoskelet Disord. 2018; 19: 204

• Hamilton J.L.
• Nagao M.
• Levine B.R.
• Chen D.
• Olsen B.R.
• Im H.J.

Targeting VEGF and its receptors for the treatment of osteoarthritis and associated pain.

J Bone Miner Res. 2016; 31: 911-924

• Hulse R.P.

Role of VEGF-A in chronic pain.

Oncotarget. 2017; 8: 10775-10776

• Llorián-Salvador M.
• González-Rodríguez S.

Painful understanding of VEGF.

Front Pharmacol. 2018; 9: 1267

• Csaky K.
• Do D.V.

Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.

Am J Ophthalmol. 2009; 148: 647-656

• Callaghan B.C.
• Cheng H.
• Stables C.L.
• Smith A.L.
• Feldman E.L.

Diabetic neuropathy: clinical manifestations and current treatments.

Lancet Neurology. 2012; 11: 521-534

• Wong T.Y.
• Cheung C.M.G.
• Larsen M.
• Sharma S.
• Simo R.

Diabetic retinopathy.

Nat Rev Dis Primers. 2016; 216012

• Bui C.H.
• Seldin E.B.
• Dodson T.B.

Types, frequencies, and risk factors for complications after third molar extraction.

J Oral Maxillofac Surg. 2003; 61: L1379-L1389

• Dallaserra M.
• Poblete F.
• Vergara C.
• Araya I.
• Yanine N.
• Villanueva J.

Infectious postoperative complications in oral surgery. An observational study.

J Clin Exp Dent. 2020; 12: e60-e70

• Dyer T.A.

A five-year evaluation of an NHS dental practice-based specialist minor oral surgery service.

Community Dent Health. 2013; 30: 219-226

• Chuang S.K.
• Perrott D.H.
• Susarla S.M.
• Dodson T.B.

J Oral Maxillofac Surg. 2007; 65: 1685-1692

• Kumbargere Nagraj S.K.
• Prashanti E.
• Aggarwal H.
• et al.

Interventions for treating post-extraction bleeding.

Cochrane Database Syst Rev. 2018; 33: CD011930